Cubist Pharmaceuticals EVP Unloads $1,695,500 in Stock (CBST)
Cubist Pharmaceuticals (NASDAQ:CBST) EVP Steven Gilman sold 25,000 shares of the company’s stock on the open market in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $67.82, for a total value of $1,695,500.00. Following the completion of the transaction, the executive vice president now directly owns 23,540 shares of the company’s stock, valued at approximately $1,596,483. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Cubist Pharmaceuticals (NASDAQ:CBST) traded down 1.15% during mid-day trading on Thursday, hitting $68.08. 532,317 shares of the company’s stock traded hands. Cubist Pharmaceuticals has a 52 week low of $40.44 and a 52 week high of $72.64. The stock has a 50-day moving average of $65.5 and a 200-day moving average of $61.. The company has a market cap of $5.042 billion and a price-to-earnings ratio of 178.88.
Cubist Pharmaceuticals (NASDAQ:CBST) last released its earnings data on Thursday, October 17th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.07. The company had revenue of $266.00 million for the quarter, compared to the consensus estimate of $267.96 million. During the same quarter in the previous year, the company posted $0.55 earnings per share. The company’s revenue for the quarter was up 11.7% on a year-over-year basis. Analysts expect that Cubist Pharmaceuticals will post $-0.10 EPS for the current fiscal year.
A number of research firms have recently commented on CBST. Analysts at Zacks reiterated a “neutral” rating on shares of Cubist Pharmaceuticals in a research note to investors on Friday, December 27th. They now have a $70.00 price target on the stock. Separately, analysts at RBC Capital raised their price target on shares of Cubist Pharmaceuticals from $78.00 to $82.00 in a research note to investors on Friday, December 20th. They now have an “outperform” rating on the stock. Finally, analysts at Cantor Fitzgerald raised their price target on shares of Cubist Pharmaceuticals from $63.00 to $65.00 in a research note to investors on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the stock. Cubist Pharmaceuticals has an average rating of “Buy” and an average price target of $68.07.
Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.